Cerity Partners
RYTM icon

Cerity Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Cerity Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$280K Sell
3,215
-449
-12% -$43.7K ﹤0.01% 2661
2025
Q4 		$392K Buy
3,664
+700
+24% +$74.3K ﹤0.01% 2250
2025
Q3 		$299K Buy
+2,964
New +$275K ﹤0.01% 2284

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Cerity Partners's RYTM Position: Q1 2026 in Review

Cerity Partners reduced its Rhythm Pharmaceuticals (RYTM) stake by 12% in Q1 2026, selling an estimated $43.7K and leaving 3,215 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #2661.

Cerity Partners first reported a position in RYTM in Q3 2025 and has held it in 3 quarters since. The position peaked at $392K in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Cerity Partners held 3,215 shares of Rhythm Pharmaceuticals worth $280K as of Q1 2026.
  • Cerity Partners sold 449 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $43.7K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #2661 holding.
  • Cerity Partners first reported a position in Rhythm Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Cerity Partners's Rhythm Pharmaceuticals position peaked at $392K in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.